RAMUCIRUMAB for Squamous cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where RAMUCIRUMAB was used for Squamous cell carcinoma.
Most Reported Side Effects for RAMUCIRUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 743 | 13.9% | 343 | 243 |
| Death | 492 | 9.2% | 492 | 51 |
| Interstitial lung disease | 269 | 5.0% | 55 | 131 |
| Febrile neutropenia | 229 | 4.3% | 70 | 148 |
| Neutropenia | 229 | 4.3% | 45 | 58 |
| Decreased appetite | 187 | 3.5% | 37 | 96 |
| Diarrhoea | 186 | 3.5% | 34 | 92 |
| Hypertension | 175 | 3.3% | 31 | 58 |
| Pyrexia | 161 | 3.0% | 27 | 107 |
| Nausea | 160 | 3.0% | 39 | 69 |
| Fatigue | 159 | 3.0% | 28 | 55 |
| Disease progression | 153 | 2.9% | 39 | 31 |
| Ascites | 152 | 2.8% | 40 | 74 |
| Neutrophil count decreased | 150 | 2.8% | 30 | 72 |
| Off label use | 148 | 2.8% | 30 | 49 |
Other Indications for RAMUCIRUMAB
Gastric cancer (1,257)
Product used for unknown indication (780)
Non-small cell lung cancer (405)
Lung neoplasm malignant (304)
Adenocarcinoma gastric (264)
Colon cancer (222)
Gastric cancer stage iv (178)
Oesophageal adenocarcinoma (158)
Hepatocellular carcinoma (156)
Metastatic gastric cancer (156)
Other Drugs Used for Squamous cell carcinoma
CARBOPLATIN (608)
CISPLATIN (522)
PACLITAXEL (496)
PEMBROLIZUMAB (470)
FLUOROURACIL (430)
NIVOLUMAB (343)
CETUXIMAB (283)
CEMIPLIMAB-RWLC (234)
DOCETAXEL (198)
GEMCITABINE (109)